MX2021000002A - Complejo para mejorar la respuesta inmune. - Google Patents
Complejo para mejorar la respuesta inmune.Info
- Publication number
- MX2021000002A MX2021000002A MX2021000002A MX2021000002A MX2021000002A MX 2021000002 A MX2021000002 A MX 2021000002A MX 2021000002 A MX2021000002 A MX 2021000002A MX 2021000002 A MX2021000002 A MX 2021000002A MX 2021000002 A MX2021000002 A MX 2021000002A
- Authority
- MX
- Mexico
- Prior art keywords
- complex
- molecular weight
- polyethylene glycol
- immune response
- amino compounds
- Prior art date
Links
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 125000002091 cationic group Chemical group 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- 230000001937 non-anti-biotic effect Effects 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- 229920002873 Polyethylenimine Polymers 0.000 abstract 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810698033.6A CN108743938B (zh) | 2018-06-29 | 2018-06-29 | 用于增强免疫响应的复合物的制备方法 |
| CN201810700708.6A CN109078180B (zh) | 2018-06-29 | 2018-06-29 | 用于增强免疫响应的复合物 |
| PCT/CN2019/093558 WO2020001587A1 (zh) | 2018-06-29 | 2019-06-28 | 用于增强免疫响应的复合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000002A true MX2021000002A (es) | 2021-05-12 |
Family
ID=68984509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000002A MX2021000002A (es) | 2018-06-29 | 2019-06-28 | Complejo para mejorar la respuesta inmune. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12178871B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3818990A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7296644B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102631084B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019296320B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020026976A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3105281A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021000002A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11202013185VA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020001596A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202100026B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7296644B2 (ja) | 2018-06-29 | 2023-06-23 | 信福(北京)医▲薬▼科技有限公司 | 免疫応答を強化するための複合物の調製方法 |
| WO2025076078A1 (en) * | 2023-10-03 | 2025-04-10 | The General Hospital Corporation | Methods of central nervous system administration of compositions comprising a cell therapy and dimethyl sulfoxide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056315C (zh) | 1993-05-31 | 2000-09-13 | 林海祥 | 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗 |
| ES2259914B1 (es) | 2005-03-14 | 2007-06-16 | Advanced In Vitro Cell Technologies, S.L. | Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas. |
| CN103405762A (zh) * | 2005-06-08 | 2013-11-27 | 依生生物制药(新加坡)私人有限公司 | 以聚肌苷酸-聚胞苷酸为主的佐剂 |
| KR101203401B1 (ko) | 2005-06-08 | 2012-11-22 | 이쉥 바이오파마(싱가포르)피티이 리미티드 | 폴리이노신산-폴리시티딜산-기초 보조제 |
| US20070166239A1 (en) | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
| US20070166800A1 (en) | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| CN101134014A (zh) | 2007-09-19 | 2008-03-05 | 天津大学 | 带有表面涂层的硫酸钙串珠植入型局部释药体系及制备方法 |
| CN101293933B (zh) | 2008-06-17 | 2011-05-04 | 浙江大学 | 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用 |
| CN102318740B (zh) | 2011-07-15 | 2012-11-21 | 山东省农业科学院畜牧兽医研究所 | 复合氨基酸多维液体微乳及其制备方法 |
| SG11201406208QA (en) | 2012-05-03 | 2014-11-27 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| CN103599071B (zh) * | 2013-11-08 | 2016-01-27 | 杭州美亚药业股份有限公司 | 一种双链聚肌胞干粉的制备方法 |
| EP3083962B1 (en) * | 2013-12-16 | 2021-08-18 | RiboxX GmbH | Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment |
| CN104434784B (zh) | 2014-11-15 | 2017-07-04 | 成都天台山制药有限公司 | 聚肌胞注射液药物组合物和制法 |
| CN105396130A (zh) | 2015-11-10 | 2016-03-16 | 林海祥 | 皮氨钙佐剂及含有皮氨钙佐剂的疫苗 |
| CN107184973A (zh) | 2016-03-15 | 2017-09-22 | 中国医学科学院基础医学研究所 | 一种复合疫苗佐剂及其应用 |
| CN106075431A (zh) | 2016-03-23 | 2016-11-09 | 林海祥 | 皮氨钙联合佐剂及含有皮氨钙联合佐剂的疫苗 |
| US10512687B2 (en) | 2016-04-01 | 2019-12-24 | Colorado State University Research Foundation | Compositions and methods for enhanced innate immunity |
| CN107875168B (zh) * | 2016-09-30 | 2022-03-04 | 广州百吉生物制药有限公司 | 一种免疫调节组合物在治疗恶性积液中的用途 |
| RU2647366C1 (ru) | 2017-04-12 | 2018-03-15 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук" (ФИЦ Биотехнологии РАН) | Антиагрегантное средство |
| CN109125264B (zh) | 2017-06-19 | 2020-10-30 | 林海祥 | 一种抗感染抗肿瘤的粘膜免疫制剂 |
| CN109078180B (zh) * | 2018-06-29 | 2019-05-31 | 信福(北京)医药科技有限公司 | 用于增强免疫响应的复合物 |
| JP7296644B2 (ja) | 2018-06-29 | 2023-06-23 | 信福(北京)医▲薬▼科技有限公司 | 免疫応答を強化するための複合物の調製方法 |
| CN108743938B (zh) | 2018-06-29 | 2019-04-09 | 信福(北京)医药科技有限公司 | 用于增强免疫响应的复合物的制备方法 |
-
2019
- 2019-06-28 JP JP2020573468A patent/JP7296644B2/ja active Active
- 2019-06-28 US US17/256,979 patent/US12178871B2/en active Active
- 2019-06-28 AU AU2019296320A patent/AU2019296320B2/en active Active
- 2019-06-28 US US17/256,980 patent/US12226477B2/en active Active
- 2019-06-28 SG SG11202013185VA patent/SG11202013185VA/en unknown
- 2019-06-28 JP JP2020573491A patent/JP7366434B2/ja active Active
- 2019-06-28 KR KR1020217002973A patent/KR102631084B1/ko active Active
- 2019-06-28 CA CA3105281A patent/CA3105281A1/en active Pending
- 2019-06-28 MX MX2021000002A patent/MX2021000002A/es unknown
- 2019-06-28 BR BR112020026976-0A patent/BR112020026976A2/pt unknown
- 2019-06-28 SG SG11202013183UA patent/SG11202013183UA/en unknown
- 2019-06-28 EP EP19825645.5A patent/EP3818990A4/en not_active Withdrawn
- 2019-06-28 WO PCT/CN2019/093607 patent/WO2020001596A1/zh not_active Ceased
- 2019-06-28 CA CA3105283A patent/CA3105283A1/en active Pending
- 2019-06-28 KR KR1020217002989A patent/KR102704088B1/ko active Active
- 2019-06-28 EP EP19825644.8A patent/EP3815713A4/en not_active Withdrawn
- 2019-06-28 WO PCT/CN2019/093558 patent/WO2020001587A1/zh not_active Ceased
-
2021
- 2021-01-04 ZA ZA2021/00026A patent/ZA202100026B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202100026B (en) | 2021-10-27 |
| US12226477B2 (en) | 2025-02-18 |
| KR20210025095A (ko) | 2021-03-08 |
| KR102631084B1 (ko) | 2024-01-29 |
| EP3818990A4 (en) | 2022-05-04 |
| JP7366434B2 (ja) | 2023-10-23 |
| JP2021529787A (ja) | 2021-11-04 |
| KR20210025096A (ko) | 2021-03-08 |
| AU2019296320B2 (en) | 2023-10-12 |
| SG11202013185VA (en) | 2021-01-28 |
| US20240316189A9 (en) | 2024-09-26 |
| EP3815713A4 (en) | 2022-04-06 |
| EP3818990A1 (en) | 2021-05-12 |
| JP2021529789A (ja) | 2021-11-04 |
| JP7296644B2 (ja) | 2023-06-23 |
| CA3105283A1 (en) | 2020-01-02 |
| SG11202013183UA (en) | 2021-01-28 |
| WO2020001587A1 (zh) | 2020-01-02 |
| CA3105281A1 (en) | 2020-01-02 |
| US12178871B2 (en) | 2024-12-31 |
| WO2020001596A1 (zh) | 2020-01-02 |
| AU2019296320A1 (en) | 2021-01-28 |
| BR112020026976A2 (pt) | 2021-05-25 |
| US20220072124A1 (en) | 2022-03-10 |
| KR102704088B1 (ko) | 2024-09-09 |
| EP3815713A1 (en) | 2021-05-05 |
| US20230210893A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4223316A3 (en) | Improved antibody-oligonucleotide conjugate | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| AR068816A1 (es) | Composiciones de brimonidina mejorada para el tratamiento del eritema | |
| JP2009502355A5 (cg-RX-API-DMAC7.html) | ||
| MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
| JP2014240439A5 (cg-RX-API-DMAC7.html) | ||
| UA104634C2 (xx) | Пегильована l-аспарагіназа $пегилированная l-аспарагиназа | |
| EP2827863B1 (en) | Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| MY188825A (en) | High-concentration monoclonal antibody formulations | |
| AR074196A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| RU2016139373A (ru) | Растворы бупренорфина с замедленным высвобождением | |
| JP2015518818A5 (cg-RX-API-DMAC7.html) | ||
| NZ588913A (en) | Liver cancer drug | |
| NZ700182A (en) | Parenteral formulations for administering macrolide antibiotics | |
| RU2018146395A (ru) | Препараты полиалкиленоксид-аспарагиназы и способы их получения и применение | |
| RU2366450C1 (ru) | Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций | |
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| Fan et al. | Injectable thermosensitive iodine‐loaded starch‐g‐poly (N‐isopropylacrylamide) hydrogel for cancer photothermal therapy and anti‐infection | |
| KR20190101954A (ko) | ExPEC 글리코콘쥬게이트 백신 제형 | |
| MX2010002448A (es) | Formulacion liquida del g-csf conjugado. | |
| JP2019537589A5 (cg-RX-API-DMAC7.html) | ||
| NZ703919A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| NZ591496A (en) | A medicinal comprising ibuprofen and paracetamol and treatment for arthritis | |
| CN105435221B (zh) | 一种针对血管内皮生长因子的人源化抗体的药物组合物 | |
| RU2010114841A (ru) | Селенсодержащий препарат для профилактики и лечения микроэлементоза у сельскохозяйственных животных и птиц |